Therefore, given the information we currently have regarding the alteration in the number and location of subtypes of the β- receptors in HF, specific targeting of β-ARs, perhaps differing over the course of HF progression, may offer an interesting solution. The gene discussed is CTBP1; the disease is hydrops fetalis.